Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
June 2nd, 2023
Presented here is a protocol for using silver nanoparticles to effectively ameliorate the acute symptoms of type II collagenase-induced osteoarthritis mice, including synovial inflammation, synovial hyperplasia, vascular hyperplasia, etc.
This method has a potential to be utilized as a new clinical strategy for knee osteoarthritis. This technique is safe, simple for local injections, and the treatment is effective in animal experimentation. Silver nanoparticles might be applicable in other inflammation disease and it needs further research.
It is important then to be careful when injecting the knee size of the mice, ensuring the correct procedure. Assessing the hand fill of the knee joint at the knees and avoid any drug leakage. Begin by placing an anesthetized mouse on a surgical table.
Tape the limbs of the mouse, then shave the fur with a razor. Next, disinfect the shaved region thrice with alternating scrubs of 0.1%iodoform and alcohol. Using scissors, make an incision on the skin, sequentially exposing the subcutaneous tissue and the infra patella ligament.
With a one milliliter insulin syringe, inject 10 units of type two collagenase into the joint cavity. Suture the subcutaneous tissue, then suture the skin. Now sterilize the sutured area with 0.1%iodoform.
Place the mouse into individually ventilated cages once they wake up from the anesthesia. Start by adding 400 microliters of type one collagen to a 1.5 milliliter micro centrifuge tube placed on ice. Now, add 200 microliters of PBX, mix well and place the tubes on ice.
Add 400 microliters of silver nanoparticles to this suspension, making the final nanoparticle concentration to one milli mole. Mix the suspension well. One week after the collagenase injection, remove the KOA mice from their cages.
Before injecting silver nanoparticles, anesthetize and surgically prepare the mouse as previously demonstrated. Use scissors to sequentially expose the skin, subcutaneous tissue and knee ligaments. Then, using the needle of a one milliliter insulin syringe, enter the joint cavity at a 15 degree angle and slowly inject 20 microliters of the silver nanoparticle collagen mixture.
During the injection, the knee joint will swell, ensuring a successful drug injection. After suturing and sterilizing the surgical site as earlier, place the mice into individually ventilated cages once the anesthesia wears off. Surgically sterilize and dissect the limbs of the euthanized mouse.
Harvest the knee joints including the femur and tibia, and remove the muscle tissue. Collect the knee joint tissues, including the femur and tibia and the surrounding soft ligament. Encapsule in 10%formalin for preservation and fixation.
After overnight fixation of the tissues, embed the sections in paraffin. Using a microtome, cut the embedded tissues into 0.4 micro thick sections. Subject the tissues to different staining techniques.
The average body weight of the KOA mice was significantly lower than that of the mice in the control group. The average body weight of the mice in the type two collagenase and silver nanoparticle group was higher compared to the KOA mice. HE staining showed that the synovial thickness of the mice in the KOA group was significantly higher compared with the control group.
The synovial thickness of the group treated with nanoparticles was reduced relative to the KOA group. Vascular hyperplasia of the synovium was observed in the KOA group and was found to be significantly reduced in the nanoparticle treated group. Safranin-O staining revealed a destroyed cartilage matrix in KOA mice, while the mice treated with the nanoparticle collagen mixture showed a significantly better cartilage matrix.
Morphological feature scores were higher in the collagen II treated group relative to the control group. Immunohistochemical staining demonstrated reduced neutrophil infiltration in the synovial regions of the nanoparticle treated mice as compared to the KOA group. It is important to avoid drug blockage during the injection of type II collagenase and several nanoparticles.
The therapeutic effect of several nanoparticles could be attempted on animal models of anterior cruciate ligament injury.
Overview
This article presents a protocol for utilizing silver nanoparticles to alleviate acute symptoms of type II collagenase-induced osteoarthritis in mice. The method demonstrates effectiveness in reducing synovial inflammation and hyperplasia.
Key Study Components
Area of Science
- Neuroscience
- Biology
- Osteoarthritis Research
Background
- Type II collagenase-induced osteoarthritis is a common model for studying knee osteoarthritis.
- Silver nanoparticles have shown promise in treating inflammation.
- Local injection techniques are crucial for effective treatment.
- Further research is needed to explore the applicability of silver nanoparticles in other inflammatory diseases.
Purpose of Study
- To evaluate the effectiveness of silver nanoparticles in treating osteoarthritis symptoms in mice.
- To establish a safe and simple injection protocol for local treatment.
- To assess the potential for broader applications in inflammatory diseases.
Methods Used
- Injection of type II collagenase into the knee joint of anesthetized mice.
- Preparation of a silver nanoparticle-collagen mixture for subsequent injection.
- Assessment of synovial thickness and cartilage matrix integrity through histological staining.
- Monitoring of body weight changes in treated versus control groups.
Main Results
- Significant reduction in synovial thickness in nanoparticle-treated mice compared to the KOA group.
- Improvement in cartilage matrix integrity observed in treated mice.
- Reduced neutrophil infiltration in the synovial regions of nanoparticle-treated mice.
- Body weight of nanoparticle-treated mice was higher than that of KOA mice.
Conclusions
- Silver nanoparticles effectively ameliorate symptoms of osteoarthritis in mice.
- The injection method is safe and can be easily performed.
- Further studies are warranted to explore the therapeutic potential in other inflammatory conditions.
Frequently Asked Questions
Executive Industry Relevance
Silver nanoparticle administration in a mouse model of knee osteoarthritis demonstrates a novel approach for modulating inflammatory pathways and synovial pathology in preclinical disease-relevant systems. Quantitative histological and immunohistochemical outputs provide predictive confidence for early-stage target validation and mechanistic de-risking. This protocol supports translational continuity from discovery biology to preclinical assessment in inflammatory joint disease portfolios.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of inflammatory mechanisms and synovial hyperplasia in osteoarthritis models.
- Supports functional target validation by quantifying neutrophil infiltration and synovial thickness.
- Provides mechanistic de-risking for anti-inflammatory strategies in degenerative joint disease.
Screening & Assay Development
- Establishes a validated in vivo system for evaluating anti-inflammatory agents in joint pathology.
- Delivers reproducible quantitative readouts via histological and immunohistochemical staining.
- Facilitates assay standardization for compound screening in inflammatory disease models.
Translational & Preclinical Research
- Aligns with disease-relevant endpoints such as cartilage matrix integrity and synovial vascularization.
- Enables risk-adjusted advancement decisions based on quantitative tissue-level outcomes.
- Supports continuity from mechanistic discovery to preclinical proof-of-concept in osteoarthritis research.
Pipeline & Workflow Integration
This protocol integrates from early discovery through preclinical validation, supporting lead identification and mechanistic de-risking in inflammatory joint disease pipelines.
- Discovery Biology: Quantifies inflammatory cell infiltration and synovial changes to clarify therapeutic hypotheses.
- Screening: Provides standardized, reproducible in vivo readouts for anti-inflammatory compound evaluation.
- Analytics: Enables statistical comparison of synovial thickness, cartilage integrity, and immune cell presence across groups.
- Translational Research: Connects mechanistic findings to preclinical endpoints relevant for osteoarthritis progression.
- Enterprise Reuse: Offers a reusable in vivo platform for testing diverse anti-inflammatory modalities in joint disease models.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in anti-inflammatory target validation and reduces mechanistic ambiguity.
- Operational Value: Standardizes in vivo procedures and quantitative tissue analysis for reproducibility.
- Strategic Value: Informs go/no-go decisions and reduces late-stage biological risk in osteoarthritis portfolios.
- Portfolio Impact: Supports risk-adjusted prioritization of anti-inflammatory strategies for degenerative joint diseases.
Implementation Considerations
- Requires expertise in small animal surgery and local joint injection techniques.
- Needs access to histological and immunohistochemical analysis infrastructure.
- Demands cross-team standardization of injection and tissue processing protocols.
- Adaptation may be needed for other inflammatory or degenerative joint models.
- Careful handling is essential to avoid drug leakage or injection errors in small joints.
Biopharma FAQs
Chapters in this video
0:00
Introduction
0:44
Knee Osteoarthritis (KOA) Mouse Model Establishment
1:41
Synthesis of Silver Nanoparticle and Treatment of Collagenase‐Induced KOA Mice
3:10
Staining of the Collected Knee Joint and Synovial Tissue
3:55
Results: Comparative Analysis of KOA and Silver Nanoparticle‐Treated Murine Groups
5:24
Conclusion
